Therefore, strategies combining endocrine therapy or HER2-Neu blockade with IL-6 pathway inhibition would be plausible therapeutic approaches to significantly improve relapse-free survival of patients diagnosed with these breast cancer subtypes. This evidence concerns the gene ERBB2 and breast cancer.